Total
0
Shares
Medlab (ASX:MDC)- CEO, Sean Hall
CEO, Sean Hall
Source: Medlab
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform
  • Essentially, NanoCelle delivers drug formulations via an oral spray
  • So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes
  • It can also potentially lower drug dosages and reduce the side effects of some formulations
  • Medlab has also filed patent applications in other jurisdictions, such as the U.S., Europe and New Zealand
  • On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share

Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform.

Essentially, NanoCelle delivers drugs via an oral spray. The device sprays the formulation into the Oro-buccal membrane, which is located along the lining of the cheek and the roof of the mouth.

So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes. It can also potentially lower drug dosages and reduce the side effects of some formulations

Source: Medlab

Medlab CEO, Sean Hall, is pleased with the patent and says NanoCelle is a key feature in Medlab’s leading drug, NanaBis.

“This is the first patent granted for our NanoCelle drug delivery platform, it is a huge validation of the science behind NanoCelle and its innovative mode of action,” he said.

“NanoCelle is used to greatly improve drug solubility issues resulting in improved absorption, metabolism and utilisation, giving us [Medlab] many options to improve prescription and over the counter medicines,” he added.

Medlab has also filed patent applications in the U.S., Europe, New Zealand, Canada, Hong Kong and Singapore.

On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share at 2:06 pm AEST.

MDC by the numbers
More From The Market Herald
Amplia Therapeutics - CEO and MD, John Lambert

" Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan.
Creso Pharma (ASX:CPH) - Creso Pharma

" Creso Pharma’s (ASX:CPH) Halucenex secures Dealer’s Licence amendment

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence.

" Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) granted ethics approval for chronic pain trial

Zelira Therapeutics (ZLD) has received ethics approval for its Phase 2a clinical trial for chronic pain.